

A Deprescribing Initiative to Reduce Risk of Hypoglycemia in Long-term Care Residents

V Ogundipe MD, N Khosrodad MD, C Uhlar MD, R Begum MD, A Montoya MD MPH CMD, J Beal DO FACOI CMD Division of Geriatric and Palliative Medicine, University of Michigan

Introduction and Objectives

- Polypharmacy affects many older adults in Long Term Care (LTC) and can lead to adverse drug events like hypoglycemia.
- The American Diabetes Association (ADA) recommends higher hemoglobin A1c targets for older adults with multiple comorbidities and poor functional status.
- The Drive to Deprescribe initiative targets reduction of antihyperglycemic agents to improve quality of life and reduce risk of hypoglycemia for LTC residents.
- Our primary objective was to safely change, reduce, or stop one or more antihyperglycemic medications in at least 25% of at-risk patients. The secondary objective was to reduce unnecessary blood glucose checks and insulin administrations.

Methods

- 215-bed nursing home in Southeast Michigan
- 21 LTC residents on antihyperglycemic agents
- PDSA (Plan, Do, Study, Act) model used

Data for 30 days pre-/post-intervention:

- Hypoglycemic events (<70 mg/dL)
- Pre-hypoglycemic events (70-100 mg/dL)
- Hyperglycemic events (>250 mg/dL)
- Recent hemoglobin A1C
- Average number blood glucose checks/day
- Average number insulin administrations/day

Deprescribing plan implemented (see right)

- Monitoring for hypo-/hyperglycemic events
- HbA1C 90 days post intervention

requires frequent sliding scale insulin Decrease by 50%. Add non-insulin agent

Replace with mealtime insulin if patient

- If metformin tolerated/GFR >45. start. If not choose second line agent (TZD, DPP4, GLP-1, SGLT2)
- Decrease by 2 units re-evaluate after 2 weeks and change by 2 units PRN for FBG 100-200 If basal insulin less than 10 U stop and add noninsulin agent
- Add non-insulin agent If metformin tolerated/GFR >45, start. If not choose second line agent (TZD, DPP4, GLP-1, SGLT2)

If not tolerated and/or GFR <30



Figure 1. Number of antihyperglycemic agents before and after deprescribing intervention





Figure 2. Number of patients below, at or above target hemoglobin A1C before and after intervention



*Target HbA1C is based on ADA standards of medical care for diabetes in older adults



Discussion

- Implementation of individualized deprescribing plans led to stopping one or more unnecessary antihyperglycemic agents in 81% (17/21) of patients, decreased frequency of BG checks in 57% (12/21) and discontinuation of sliding scale insulin by 100% (3/3).
- Three participants were not included in the post-intervention results as two passed away and one declined to participate.
- After discontinuing unnecessary BG checks, the average number of BG checks per day over 30 days decreased from 0.85 to 0.46.
- More patients were at their target HbA1C after compared to before the intervention [39% (7/18) vs 24% (5/21)]. Following the intervention, most patients remained below target HbA1C [61% (11/18)].
- Study limitations included: Difficulty obtaining accurate records of BG checks due to multiple recording sites. Limited time and resources made it challenging to obtain buyin from patients and providers.

Conclusions

- Individualized deprescribing plans led to reduction of antihyperglycemic agents, decrease in unnecessary BG checks, and improvement in achieving target HbA1C.
- Benefits of this intervention likely include improved quality of life for patients, a decrease in nursing duties, and cost reduction.
- Future studies should focus on standardizing documentation of BG, hypoglycemia protocols, and continued education and efforts towards deprescribing in LTC settings.

We acknowledge the efforts of front-line healthcare workers in LTC. The authors have no financial interests that relate to the research presented in this poster. For questions, contact Vanessa Ogundipe, MD vogundip@med.umich.edu